Diabetes, weight loss drug companies growth far from over, says ClearBridge analyst

ClearBridge research analyst Marshall Gordon sits down with InvestmentNews anchor Gregg Greenberg to discuss the rise of new diabetes and weight-loss drugs, as well as the best ways to invest in this burgeoning sector.
More: IN THE NASDAQ
Will the economy remain resilient as consumers grow constrained?

Will the economy remain resilient as consumers grow constrained?

Don’t dismiss foreign stocks due to spike in energy prices

Don’t dismiss foreign stocks due to spike in energy prices

EY: Recent liquidity and credit concerns won’t sink private market asset growth

EY: Recent liquidity and credit concerns won’t sink private market asset growth